| 27999210 |
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Blosser, W,
Vakana, E,
Simpson, N,
Stancato, LF,
Huber, L,
Zhang, Y,
Dowless, M,
Manro, J,
Pratt, S,
Jaken, S,
Stephens, J,
Yuan, XJ,
Peng, SB
|
Oncotarget |
2017 |
| 26343583 |
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
McCann, D,
Huber, L,
Peng, SB,
Webster, Y,
Buchanan, S,
Plowman, GD,
Rutkoski, TJ,
Vogeti, S,
Smith, BD,
Yadav, V,
Flynn, DL,
Ma, X,
Kays, L,
Patel, P,
Yin, T,
Zhang, Y,
Chun, L,
Walgren, J,
Lu, WP,
Gong, X,
Kaufman, MD,
Starling, JJ,
Conti, I,
Wise, S,
Zhang, X,
Van Horn, RD,
Donoho, GP,
Chen, SH,
Mochalkin, I,
Henry, JR
|
Cancer Cell |
2015 |
